Pharmacogenomics of the human ABC transporter ABCG2: From functional evaluation to drug molecular design

Naturwissenschaften

Volumn 92, Issue 10, 2005, Pages 451-463

  Ishikawa, Toshihisa ^a   Tamura, Ai ^a   Saito, Hikaru ^a   Wakabayashi, Kanako ^a   Nakagawa, Hiroshi ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 6 PRENYLCHRYSIN; ACACETIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CANERTINIB; CIMETIDINE; DIFLOMOTECAN; DOXORUBICIN; ELACRIDAR; FLAVONOID; FLAVOPIRIDOL; FUMITREMORGIN; GEFITINIB; GENISTEIN; GLUCURONIDE; IMATINIB; KAEMPFEROL; METHOTREXATE; MITOXANTRONE; NARINGENIN; NOVOBIOCIN; QUERCETIN; TARIQUIDAR; TECTOCHRYSIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT;

DRUG DEVELOPMENT;

CANCER RESISTANCE; DNA POLYMORPHISM; DRUG DESIGN; DRUG SCREENING; METHODOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENOMICS; REVIEW; SYNTHESIS; VALIDATION PROCESS;

ALLELES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETHNIC GROUPS; GENE FREQUENCY; HUMANS; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 28244485775     PISSN: 00281042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00114-005-0019-4     Document Type: Review

References (103)

1. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F, Di Pietro A, Pérez-Vicoria JM. (2005) Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65:4852-4860
2. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425
3. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339
4. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398
5. Bäckström G, Taipalensuu J, Melhus H, Brandstrom H, Svensson AC, Artursson P, Kindmark A (2003) Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 5:359-364
6. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD (2001) Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520:234-241
7. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, Redinbo MR (2002) Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 9:337-342
8. Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357
9. Borst P, Oude Elferink R (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592
10. Bosch TM, Kjellberg LM, Bouwers A, Koeleman BPC, Schellens JHM, Beijnen JH, Smits PHM, Meijerman I (2005) Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 5:123-131
11. Bowers AG (1999) Phytophotodermatitis. Am J Contact Dermat 10:89-93
12. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen, Schinkel AH, Schellens JHM (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): implication for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582
13. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942
14. Chen AY, Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218
15. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 14:4048-4054
16. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA (2004) Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269-275
17. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166
18. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 17:5889-5894
19. Doyle LA, Ross DD (2003) Multidrug resistance transporter from human MCF-7 breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358
20. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670
21. Elkind N, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K, Sarkadi B (2005) The multidrug transporter ABCG2 prevents tumor cell death induced by the EGF receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65:1770-1777
22. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
23. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MCR1 and MRP1. Biochim Biophys Acta 1587:318-325
24. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113
25. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 7:3473-3478
26. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 6:696-702
27. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333-2337
28. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878
29. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726
30. Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2002) Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 6:285-310
31. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 8:611-616
32. Imai Y, Tsukahara S, Asada S, Sugimoto Y (2004) Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346-4352
33. 2+-dependent cardiac transport system for glutathione S-conjugates: a study using rat heart sarcolemma vesicles. J Biol Chem 264:1733-17348
34. Ishikawa T (2003) Multidrug resistance: genomics of ABC transporters. In: Cooper DN (ed) Nature Encyclopedia of the Human Genome, vol. 4. Nature Publishing Group, London, pp 154-160
35. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S (2004b) Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure- activity relationship analyses. Drug Metab Pharmacokinet 19:1-4
36. Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S (2005b) Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des (in press)
37. Ishikawa T, Kasamatsu S, Hagiwara Y, Mitomo H, Kato R, Sumino Y (2003) Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab Pharmacokinet 18:194-202
38. Ishikawa T, Müller M, Klünemann C, Schaub T, Keppler D (1990) ATP-dependent primary active transport of cysteinyl leukotrienes across rat liver canalicular membrane: the role of glutathione S-conjugate carrier. J Biol Chem 265:19279-19286
39. Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S (2004c) Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Bio Pharm Bull 27:939-948
40. Ishikawa T, Sakurai A, Kanamori Y, Nagakura M, Hirano H, Takarada Y, Yamada K, Fukushima K, Kitajima M (2005a) High-speed screening of human ABC transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol, in press
41. Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, Wada M, Endou H, Sumino Y (2004a) The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 5:67-99
42. Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Suzuki H, Sugiyama Y, Ozawa S, Sawada J (2003) Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered Irinotecan. Drug Metab Pharmacokinet 18:212-217
43. Jitsukawa K, Suizu R, Hidano A (1984) Chlorella photosensitization. New phytophotodermatosis. Int J Dermatol 23:263-268
44. Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Oude Elferink RPJ, Rosing H, Beijnen JH, Schinkel AH (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654
45. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar W, Mesman E, Dale TC, Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129
46. Kalow E, Meyer U, Tyndale RF (2001) Pharmacogenomics. Marcel Dekker, Basel, New York
47. Kaneda N, Nagata H, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720
48. Keppler D, Jedlitschky G, Leier I (1998) Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 292:607-616
49. Kim RB, Wilkinson GR (2001) Pharmacogenomics of drug transporters. In: Kalow E, Meyer U, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker, New York, Basel, pp 81-108
50. Klein I, Sarkadi B, Váradi A (1999) An inventory of the human ABC proteins. Biochim Biophys Acta 1461:237-262
51. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 1:94-101
52. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, Sugiyama Y (2004) Functional analysis of SNP variants of BCRP/ABCG2. Pharm Res 10:1895-1903
53. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Scuetz JD (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cells survival through interaction with heme. J Biol Chem 279:24218-24225
54. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40:S3-S8
55. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP (2000) Mechanism of action of camptothecin. Ann NY Acad Sci 922:1-10
56. Ma MK, McLeod ML (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 1:41-49
57. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 8:2182-2194
58. Millard TP, Hawk JL (2002) Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol 3:239-246
59. Millard TP, Kirk A, Ratnavel R (2004) Cutaneous hyperpigmentation during therapy with hydroxychloroquine. Clin Exp Dermatol 29:92-93
60. Mitomo H, Kato R, Ito A, Kasamatsu A, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 373:767-774
61. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13
62. Mizuarai S, Aozasa N, Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2:238-246
63. Morisaki K, Robey RW, Özvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates S (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172
64. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawataba S, Soda H, Ishikawa T, Tanabe S, Kohno S (2001) Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 4:827-832
65. Noble MEM, Endicott JA, Johnson LN. (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-1805
66. Özvegy C, Varadi A, Sarkadi B (2002) Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 50:47980-47990
67. Özvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High affinity interaction of tyrosine kinase inhibitors with ABCG2 multidrug transporter. Mol Pharmacol 65:1485-1495
68. Özvegy-Laczka C, Köblös G, Sarkadi B, Varadi A (2005) Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 1668:53-63
69. Pirmohamed M (2001) Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol 4:345-347
70. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50
71. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ (1998) Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279:1504-1513
72. Salerno R, Lesko LJ (2004a) Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission. Pharmacogenomics 5:25-30
73. Salerno R, Lesko LJ (2004b) Pharmacogenomic data: FDA volutanry and required submission guidance. Pharmacogenomics 5:503-505
74. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A (2004) ABCG2, a transporter for all seasons. FEBS Lett 567:116-120
75. Schellens JH, Creemers GJ, Beijnen JH, de Rosing H, Boer-Dennert M, McDonald M, Davies E, Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73:1268-1271
76. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH (2000) Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 922:188-194
77. Schmitz G, Langmann T, Heimerl S (2001) Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res 42:1513-1520
78. Service RF (2004) Surviving the blockbuster syndrome. Science 303:1796-1799
79. Sesink ALA, Arts ICW, de Boer VCJ, Breedveld P, Schellens JHM, Hollman PCH, Russel FGM (2005) Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 67:1999-2006
80. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Muzuta Y, Murase K, Yoshida H, Ross DD, Kohno S. (2004) Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108:146-151
81. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 1:38-44
82. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491-7499
83. Stewart L, Redinbo MR, Qiu X, Hol WGJH, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534-1541
84. Szuromi P, Vinson V, Marshall E (2004) Rethinking drug discovery. Science 303:1796-1799
85. Takahashi T, Nakai K, Doi T, Yasunaga M, Nakagawa H, Ishikawa T (2005) Synthesis and evaluation of 3D templates based on a taxane skeleton to circumvent P-glycoprotein-associated multidrug resistance of cancer. Bioorg Med Chem 15:2601-2605
86. Taylor JG, Choi EH, Foster CB, Chanock SJ (2001) Using genetic variation to study human disease. Trends Mol Med 11:507-512
87. Vanhoefer V, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 5:1501-1518
88. Varadi A, Tusnady G, Sarkadi B (2003) Membrane topology of the human ABC transporter proteins. In: Holland IB, Cole SPC, Kuchler K, Higgins CF (eds) ABC proteins: from bacteria to man. Academic Press, Amsterdam, pp 37-46
89. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 17:5035-5040
90. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890
91. Wang N, Lan D, Chen W, Matsuura F, Tall AR (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101:9774-9779
92. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y (2004) Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3:1119-1125
93. Yang CH, Chen YC, Kuo ML (2003) Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantron. Anticancer Res 23:2519-2523
94. Yoshikawa M, Yabuuchi H, Kuroiwa A, Ikegami Y, Sai Y, Tamai I, Tsuji A, Matsuda Y, Yoshida H, Ishikawa T (2002) Molecular and cytogenetic characterization of the mouse ATP-binding cassette transporter abcg4. Gene 293:67-75
95. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T (2004a) Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 4:25-35
96. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S (2004b) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 110:921-927
97. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 1:19-28
98. Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CE (1999) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 6:454-460
99. Zhang S, Yang X, Morris ME (2004a) Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216
100. Zhang S, Yang X, Morris ME (2004b) Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 21:1263-1273
101. Zhou S, Schuetz JD, Bunting KD, Colapietro A-M, Sampath J, Morris J, Lagutina I, Grosveld GC, Dsawa M, Nakuchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034
102. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP (2002) Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantron in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99:12339-12344
103. Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP (2005) Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105:2571-2576